Rethinking COPD: Experts Propose “Chronic Nonspecific Lung Disease” as a More Accurate Term
Table of Contents
A new diagnostic approach to chronic obstructive pulmonary disease (COPD) is challenging the very definition of the condition, prompting calls to rename it chronic nonspecific lung disease. Leading researchers suggest the current understanding of COPD is too narrow, failing to encompass the wide range of respiratory ailments that fall under its umbrella.
The debate stems from a proposal by the COPDGene 2025 Diagnosis Working Group and the CanCOLD Investigators for a multidimensional diagnostic approach. This framework includes a category for patients without evidence of airflow obstruction – a hallmark traditionally considered essential for a COPD diagnosis. This shift sparked a fundamental question, as articulated by Dr. Polverino in a related editorial: “If airflow obstruction is no longer essential for diagnosis, should we still be calling it COPD?”
The Limitations of Current Definitions
For over half a century, the term “chronic nonspecific lung disease” existed as a potential alternative, designed to encompass conditions like chronic bronchitis, asthma, emphysema, and various forms of irreversible or persistent obstructive lung disease. The renewed interest in this older terminology reflects a growing recognition of the significant clinicopathologic heterogeneity within both the “COPD” and “asthma” classifications.
“There is substantial clinicopathologic heterogeneity within the current rubric ‘COPD’,” one expert noted. This means that patients diagnosed with COPD can present with vastly different symptoms, underlying causes, and disease progression, making a single, unifying diagnosis increasingly problematic.
A Shift Towards Personalized Treatment
The proposed change isn’t merely semantic. It reflects a broader move towards personalized medicine in respiratory care. Researchers are increasingly focused on treatable traits – specific characteristics of a patient’s disease that can be targeted with tailored therapies. This approach prioritizes individual biology over rigid diagnostic categories.
This new paradigm acknowledges that focusing on specific, actionable features of a patient’s condition – rather than simply labeling it as “COPD” or “asthma” – can lead to more effective treatment strategies. The emphasis is shifting from what disease a patient has to how their disease manifests and what can be done to address it.
A Return to a Broader Framework?
In light of these developments, a compelling solution has emerged. “I propose an even deeper answer to the deep question posed earlier: call it chronic nonspecific lung disease,” one researcher suggested. This return to a broader, more inclusive term could better reflect the complex reality of chronic airway diseases and facilitate a more nuanced and effective approach to diagnosis and treatment.
The potential renaming of COPD to chronic nonspecific lung disease represents a significant step towards a more accurate and patient-centered approach to respiratory medicine, acknowledging the limitations of current classifications and embracing the promise of personalized care.
Related reading
- Step Therapy, Explained: Why Insurers Make You 'Fail First' (daybreakwire.com)
